Endry H T Lim
Overview
Explore the profile of Endry H T Lim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Amstel R, Slim M, Lim E, Ruckinger S, Seymour C, Burnett B, et al.
Crit Care
. 2024 Jun;
28(1):210.
PMID: 38943192
In a phase 3 trial (PANAMO, NCT04333420), vilobelimab, a complement 5a (C5a) inhibitor, reduced 28-day mortality in mechanically ventilated COVID-19 patients. This post hoc analysis of 368 patients aimed to...
2.
C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Differences Between PANAMO and FORCE Study
Lim E, Vlaar A, Brouwer M, van de Beek D
Crit Care Med
. 2023 Oct;
51(11):e243-e244.
PMID: 37902353
No abstract available.
3.
Lim E, Vlaar A, Brouwer M, van de Beek D
Immunobiology
. 2023 Sep;
228(6):152743.
PMID: 37717470
No abstract available.
4.
Lim E, Vlaar A, de Bruin S, Ruckinger S, Thielert C, Habel M, et al.
Intensive Care Med Exp
. 2023 Jun;
11(1):37.
PMID: 37332066
Background: Vilobelimab, a complement 5a (C5a)-specific monoclonal antibody, reduced mortality in critically ill COVID-19 patients in a phase 3 multicentre, randomized, double-blind, placebo-controlled study. As part of the study, vilobelimab...
5.
Lim E, Vlaar A, Brouwer M, van de Beek D
Lancet Respir Med
. 2023 Jun;
11(9):e80.
PMID: 37307842
No abstract available.
6.
Michels E, van Amstel R, van Linge C, Schuurman A, Reijnders T, Sulzer T, et al.
Eur Respir J
. 2023 Apr;
62(1).
PMID: 37080568
Background: Coronavirus disease 2019 (COVID-19)-induced mortality occurs predominantly in older patients. Several immunomodulating therapies seem less beneficial in these patients. The biological substrate behind these observations is unknown. The aim...
7.
Lim E, Vlaar A, de Bruin S, Brouwer M, van de Beek D
Expert Rev Anti Infect Ther
. 2023 Mar;
21(6):685-686.
PMID: 36989394
No abstract available.
8.
Asmus E, Karle W, Brack M, Wittig C, Behrens F, Reinshagen L, et al.
Eur Respir J
. 2023 Mar;
61(3).
PMID: 36958745
No abstract available.
9.
Lim E, Vlaar A, Bos L, van Vught L, Tuip-de Boer A, Dujardin R, et al.
Respir Res
. 2022 Dec;
23(1):375.
PMID: 36566174
We recently reported in the phase 3 PANAMO trial that selectively blocking complement 5a (C5a) with vilobelimab led to improved survival in critically ill COVID-19 patients. C5a is an important...
10.
van Baarle F, de Bruin S, Bulle E, van Mourik N, Lim E, Tuip-de Boer A, et al.
Transfusion
. 2022 Oct;
62(12):2490-2501.
PMID: 36300793
Background: Transfusion-related acute lung injury (TRALI) is a severe complication of blood transfusion that is thought of as a two-hit event: first the underlying patient condition (e.g., sepsis), and then...